This working group supports access to and use of best-in-class repositories of evidence syntheses and guidance.

Terms of reference

  1. To convene on a quarterly basis the leads of best-in-class* repositories and suggest potential collaborations and enrichments that reflect everyone’s dual roles as consumers and producers
  2. To share ideas for exploiting technological innovations to increase the scope or efficiency of best-in-class repositories and improve dissemination to potential users
  3. To develop and execute approaches to elicit input from diverse end users’ (including citizens) and support the use of best-in-class inventories responsive to diverse end users’ needs** #
  4. To liaise with expert groups outside COVID-END to foster standard setting, seek input and facilitate other joint work through a platform allowing exchange
  5. To review on a quarterly basis questions arising from the COVID-END inventory (such as how equity is explicitly considered and how to act on lessons learned from pilot testing) and from the eCOVIDRecMap about lessons learned, to reduce duplication and address how they can improve their methods and impact

* will be defined by best in class group

** define who the users are (from Alric: decision maker, researcher, scientists, patients, citizens, expert groups)

# includes the ‘vertical-slice’ lens which addresses the needs of end users who seek evidence and guidance to support specific COVID-19 decisions and actions (e.g., what management is appropriate for this specific patient?)


  1. Holger Schunemann, Cochrane Canada, Canada
  2. Ruth Stewart, Africa Centre for Evidence, South Africa
  3. Alfonso Iorio, McMaster University, Canada
  4. Alric Ruether, Institute for Quality and Efficiency in Health Care (IQWiG), Germany
  5. Benjamin Kagina, Vaccines for Africa Initiative, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, South Africa
  6. Claire Allen, Evidence Aid, United Kingdom (England)
  7. Cynthia Lisée, citizen partner, Canada
  8. David Tovey, Senior Advisor, COVID-END and Editor-in-Chief, Journal of Clinical Epidemiology, United Kingdom (England)
  9. Ivan Florez, Universidad de Antioquia, Colombia and McMaster University, Canada
  10. Jerry Osheroff, ACTS, USA
  11. Jonathan Kay, Education Endowment Fund, UK (England)
  12. Sara Loree, St. Luke’s Health System, USA
  13. Sara Twaddle, University of Glasgow, UK (Scotland)
  14. Shivit Bakrania, Innocenti, UNICEF Office of Research, Italy
  15. Stacy Brody, George Washington University, USA
  16. Secretariat: Kaelan Moat, McMaster Health Forum and COVID-END Secretariat

Meeting documents

Meeting date Documents